Today: 16 May 2026
Browse Category

NASDAQ:IBIO 21 October 2025 - 13 March 2026

ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus

ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus

ImmunityBio shares jumped 10.5% to $8.64 by early afternoon Friday after the company announced completion of a scalable manufacturing process for its NK-cell therapy platform. The update follows FDA acknowledgment of a resubmitted application for expanded use of Anktiva in papillary bladder cancer and recent approval of the drug in 33 countries. Investors remain cautious due to ongoing regulatory and financial risks.
13 March 2026
·
iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

iBio, Inc. shares surged 39% Monday to close at $1.67 on heavy volume, lifting its market value to about $37.5 million. The stock traded higher pre-market Tuesday, with quotes between $1.76 and $1.81. The company reported $49.6 million in cash after a recent offering and says this will fund operations into late 2027. Lead obesity drug candidate IBIO-610 has shown fat-selective weight loss in animal studies.
9 December 2025
·
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio (NASDAQ: IBIO) traded at $0.89 midday October 21, down 63% year-to-date from $2.45 in January. Shares jumped over 20% last week after bullish “Outperform” ratings from Oppenheimer and Leerink Partners, with price targets of $5.00 and $2.00. The company reported positive preclinical results for its obesity drug IBIO-610 and raised $50 million in a recent offering. Market cap stands near $18 million.
21 October 2025
·

Stock Market Today

  • NSE Releases Withheld Payouts from May 5 Derivatives Trades
    May 16, 2026, 1:39 AM EDT. The National Stock Exchange (NSE) lifted a financial freeze on payouts linked to derivatives trades executed on May 5. The freeze was initially imposed on May 6, halting settlements tied to these transactions. This clearance restores normal payout operations for traders and brokers affected, ensuring liquidity and market confidence. The NSE's move addresses concerns related to unsettled trading positions and supports smoother market functioning.

Latest articles

Dow Drops 537 Points With After-Hours Selling Threatening Wall Street AI Rally

Dow Drops 537 Points With After-Hours Selling Threatening Wall Street AI Rally

16 May 2026
U.S. stock ETFs fell in after-hours trading Friday following a more than 1% drop in the S&P 500, Dow, and Nasdaq. Oil surged 4.2% to $105.42 a barrel and the 10-year Treasury yield hit 4.597%, fueling concerns over inflation and Fed rate hikes. Nvidia, AMD, and Intel led chip declines, while Berkshire Hathaway disclosed a $2.65 billion Delta stake and exited Amazon, Visa, and Mastercard.
Accuray inks 10-year cancer tech agreement, shares in focus

Accuray inks 10-year cancer tech agreement, shares in focus

16 May 2026
Accuray and the University of Wisconsin School of Medicine and Public Health signed a 10-year research agreement focused on Accuray’s Stellar adaptive radiotherapy platform. The announcement came after market close, with Accuray shares ending down 5.2% at $0.27. The deal follows Accuray’s recent withdrawal of fiscal 2026 guidance and ongoing financial pressures.
Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

16 May 2026
Origin Materials asked shareholders to approve a plan to liquidate and dissolve the company, estimating an initial payout of $0.61 to $3.54 per share depending on asset sales and claims. Shares rose 15% to $1.43 after the filing. The company reported a 91% drop in first-quarter revenue and warned it may not survive without the wind-down. Origin cut 59% of its workforce and CEO John Bissell stepped down May 1.
NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

16 May 2026
NextNRG reported first-quarter revenue of $21.1 million, up 29% from a year earlier, but its net loss widened to $10.8 million. Cash fell to $208,048 at quarter-end, and management warned it needs immediate capital to continue operations. Shares closed at $0.2804 on Nasdaq, down nearly 6%. Total liabilities reached $34.3 million, with a stockholders’ deficit of $22 million.
Go toTop